Posts

Trapped in the examples: Escaping intermediate generalisations in pharma patents

Reformatio in peius survives a procedural violation (T 1168/24)

New referral on claim interpretation and relevance of G1/24 to added matter confirmed (G1/26)

Human definitions versus biological reality (T 630/24)

The unforgiving gold standard: Why deleting a feature can add matter at the EPO (T 0422/23)

Pitfalls of cell therapy manufacturing IP - A case study (T 0868/23)

The UPC's approach to added matter and functional claims (Abbott v. Sibio Technology, UPC_CoA_382/2024)